Trials / Completed
CompletedNCT06703463
A Drug-Drug Interaction Study of Diltiazem and MK-1167 in Healthy Adult Participants (MK-1167-006)
A Phase 1, Open-Label, Fixed-Sequence Study to Evaluate the Effect of Multiple Doses of Diltiazem on the Single-Dose Pharmacokinetics of MK-1167 in Healthy Adult Participants
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 16 (actual)
- Sponsor
- Merck Sharp & Dohme LLC · Industry
- Sex
- All
- Age
- 19 Years – 50 Years
- Healthy volunteers
- Accepted
Summary
The goal of this study this study is to learn about the safety of MK-1167 and if people tolerate it. Researchers will compare what happens to MK-1167 in the body when it is given with and without another medicine called diltiazem.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | MK-1167 | Administered via oral capsule per dosing regimen. |
| DRUG | Diltiazem | Diltiazem hydrochloride administered at a dose of 240 mg QD via oral capsules. |
Timeline
- Start date
- 2023-10-17
- Primary completion
- 2024-02-02
- Completion
- 2024-02-02
- First posted
- 2024-11-25
- Last updated
- 2024-11-25
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06703463. Inclusion in this directory is not an endorsement.